Update on XenoPort’s Horizant – Analyst Blog – NASDAQ

by admin on September 14, 2013

Update on XenoPort's Horizant – Analyst Blog
NASDAQ
XenoPort, Inc. ( XNPT ) recently announced that gabapentin enacarbil, which is the active ingredient in Horizant, has been included in an updated treatment algorithm as an initial therapy for patients with chronic persistent restless legs syndrome

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: